The triple neurokinin receptor antagonist CS-003 inhibits neurokinin A (NKA)-induced bronchoconstriction in patients with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 415s Year: 2003
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
The cannabinoid receptor agonist, WIN 55,212-2, inhibits antigen-induced plasma extravasation in guinea pig airways Source: Annual Congress 2010 - Models of airways disease Year: 2010
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Alpha-1L, but not alpha-1H, adrenoceptor antagonist prevents allergic bronchoconstriction in guinea pigs in vivo Source: Eur Respir J 2001; 18: Suppl. 33, 104s Year: 2001
Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients Source: Eur Respir J 2004; 23: 76-81 Year: 2004
Novel triple neurokinin receptors antagonist CS-003 strongly inhibits neurokinin related responses Source: Eur Respir J 2006; 28: Suppl. 50, 115s Year: 2006
A novel TRPA1 antagonist inhibits ovalbumin-induced bronchoconstriction in guinea pig models Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models Source: Annual Congress 2010 - Models of airways disease Year: 2010
EP2 & EP4 receptor agonists inhibit the airway sensory nerves that cause cough, a potential protective control that is lost in human smokers and a pre-clinical COPD model Source: International Congress 2017 – Novel mechanisms and treatments for COPD Year: 2017
Modulatory role of tachykinin NK1 receptor in cholinergic contraction of mouse trachea Source: Eur Respir J 2003; 21: 3-10 Year: 2003
Cystenyl-leukotriene receptor antagonist (LRA) inhibits respiratory burst of human neutrophils Source: Eur Respir J 2003; 22: Suppl. 45, 316s Year: 2003
Comparison of glucocorticoid and cysteinyl leukotriene receptor antagonist treatments in the airway remodeling induced by chronic airway inflammation in guinea pigs Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019
Discovery of competitive thromboxane receptor (TP) antagonism by diclofenac in guinea pig airway and vascular tissues Source: Annual Congress 2007 - Recent advances in airway smooth muscle biology Year: 2007
Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Effects of a newly developed dual CysLT1 and CysLT2 receptor antagonist, ONO-RS-531, on antigen- and leukotriene D4 -induced contractions of isolated human bronchi Source: Eur Respir J 2005; 26: Suppl. 49, 214s Year: 2005
An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019
Nicotinic alpha-7 receptor stimulation (a7nAChR) inhibited NF-kB/STAT3/SOCS3 pathways in a murine model of asthma. Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007